[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571234":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with Carbapenem-resistant Enterobacterales (CRE) infection treated with CAZ\u002FAVI ± FOS",null,"Adult patients treated for ≥ 48 hours with CAZ\u002FAVI or CAZ\u002FAVI plus FOS for a microbiologically documented CRE infection",[13],{"name":14,"affiliation":5,"role":15},"Maddalena Giannella, MD PhD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+390512143199","maddalena.giannella@unibo.it",[22,36],{"facility":5,"status":23,"city":24,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Bologna","40138","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],11.33875,44.49381,{"lat":32,"lon":31},[35],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"facility":37,"status":23,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"Instituto de Biomedicina de Sevilla (IBiS), Hospital Virgen Macarena\u002FCSIC\u002FUniversidad de Sevilla","Seville","41013","Spain","ES",{"type":29,"coordinates":43},[44,45],-5.97317,37.38283,{"lat":45,"lon":44},[48],{"name":49,"role":18,"phone":50,"phoneExt":10,"email":51},"Fernando M Docobo Pérez, PhD","+34 954118805","fdocobo1@us.es",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571234","pkpd-relationship-of-cazavi-and-fos-in-the-treatment-of-patients-with-infections-due-to-cre-100571234",false,"NCT06717594","PK\u002FPD Relationship of CAZ\u002FAVI and FOS in the Treatment of Patients With Infections Due to CRE","PK\u002FPD Relationship of CAZ\u002FAVI and FOS in the Treatment of Patients With Infections Due to Carbapenem-resistant Enterobacterales (CRE)","CAVIFOS","Inclusion Criteria:\n\n* Signature of the informed consent\n* Age ≥ 18 years\n* Adult patients treated for ≥ 48 hours with CAZ\u002FAVI or CAZ\u002FAVI plus FOS for a microbiologically documented CRE infection\n\nExclusion Criteria:\n\n* Polymicrobial\u002Fmixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","OBSERVATIONAL","A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime\u002Favibactam (CAZ\u002FAVI) alone or with CAZ\u002FAVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and\u002For OXA-48).",[70,71],"Gram Negative Infections","Antimicrobial Resistance (AMR)",[73,74,75,76,77],"Gram negative infection","Ceftazidime\u002FAvibactam","Fosfomycin","Pharmacokinetics\u002FPharmacodynamics targets","Carbapenem-resistant Enterobacterales (CRE)","2026-06-11",{"date":80,"type":81},"2026-06-12","ACTUAL",{"date":83,"type":81},"2023-12-01",{"date":85,"type":66},"2026-12-31",{"name":5,"class":6},2]